BCL2L1 and mantle cell lymphoma: Inhibition of bromodomain extra-terminal (BET) proteins, histone deacetylases (HDACs) or protein arginine methyltransferases (PRMT5) affect expression of BCL-XL, MCL-1 and BIM and synergize in vitro and in MCL mouse models with venetoclax (Fig. 4) [83–86].